elucidated the underlying tumor rejection mechanisms for the combination therapy of PD-1 with CTLA-4 inhibitors by performing a detailed analysis of human bladder tumor samples together with murine MB49 bladder tumor model (27). The gene discussed is CTLA4; the disease is neoplasm.